

Intrathecal Nalbuphine versus Intrathecal Dexmedetomidine for Postoperative Analgesia of Lower Abdominal and Lower Limb Surgeries

Manisha Kanagarajan¹, J. Gomathy²

¹Associate Professor, Dept of Anesthesia, ACS Medical College and Hospital, Velappanchavadi, Chennai, Tamil Nadu 600077, India. ²Physician Assistant, Madras Medical Mission, Chennai, Tamil Nadu 600037, India.

Abstract

Introduction: Opioids are used as adjuncts with the local anaesthetic for longer duration of action and better postoperative analgesia [4]. Nalbuphine, is a mixed agonist-antagonist and its analgesic potency is equal to morphine and less side effects like respiratory depression, urinary retention and pruritus. Intrathecal dexmedetomidine increased the duration of analgesia. **Aim:** To compare the duration of postoperative analgesia and the incidence of side effects of intrathecal nalbuphine and intrathecal dexmedetomidine for lower abdominal and lower limb surgeries. **Materials & Methods:** 60 patients of ASA I & II, underwent lower abdominal and lower limb surgeries using spinal blockade included. Group I (n=30) patients received Inj. Bupivacaine heavy 15 mg with Inj. Nalbuphine 0.8 mg. Group II (n=30) patients received spinal anaesthesia with Inj. Bupivacaine heavy 15 mg & Inj. Dexmedetomidine (5 mics) **Results:** The mean onset of sensory block (3.5±0.7 Vs 4.2±0.8) and motor block (1.7±0.7 Vs 2.6±0.9). Both were shorter in nalbuphine group which was statistically significant. The mean duration of analgesia was longer in patients who received dexmedetomidine (197±6 min Vs 99.6±6 min), Incidence of hypotension and bradycardia were higher in dexmedetomidine group but amenable to medical management. **Conclusion:** Intrathecal nalbuphine (0.8mg) decreases the mean duration of onset of both sensory and motor block. Intrathecal dexmedetomidine prolongs the duration of analgesia but the incidence of bradycardia and hypotension are higher.

Keywords: Spinal Anaesthesia; Nalbuphine; Dexmedetomidine; Lower Abdominal; Lower Limb Surgeries.

Introduction

Regional anaesthesia, especially spinal blockade or spinal anaesthesia is mostly preferred for lower abdominal and lower extremity surgeries. It has added advantage of reduced stress response and postoperative analgesia [1,2]. Short duration of action and hypotension and bradycardia due to sympathetic blockade are the main disadvantages of spinal anaesthesia. Various drugs or adjuvants are added with the local anaesthetic drugs to increase the duration of action as well as to reduce the unwanted effects [3]. Traditionally, opioids are the most commonly used along with the local anaesthetic for

longer duration of action as well as for better postoperative analgesia [4]. Intrathecal opioids are synergistic with local anaesthetics and intensify the sensory block without increasing the sympathetic block. Drugs like morphine can provide postoperative analgesia lasting upto even 24 hours [5]. They act on the opioid-receptors in the dorsal grey matter of spinal cord, resulting in modulation of afferent pain fibres [2]. The usefulness of intrathecal opioids are limited by side effects like pruritus, nausea, vomiting, urinary retention, and delayed respiratory depression [6,7]. Pruritus is due to the activation of central μ receptors and nausea and vomiting are due to the stimulation of the δ -opioid receptors.

Corresponding Author: Manisha Kanagarajan, 10/2, Shrestha Retreat, Sathyamurthy Nagar Post, Thirumallaivoyal, Chennai - 600062, Tamil Nadu, India.
E-mail: manishabvya@gmail.com

Received on 10.05.2017, Accepted on 16.05.2017

Intrathecal fentanyl and sufentanyl are associated with fewer incidences of nausea and vomiting than intrathecal morphine [8]. Tramadol, a centrally acting narcotic analgesic has been shown to provide effective postoperative analgesia with no risk of respiratory depression after central neuraxial administration [9]. The minimal or no respiratory depressant effect is because of 6000-fold decreased affinity for μ receptors as compared with morphine [10-13].

Nalbuphine, is an opioid drug with an agonist action at μ receptor and an antagonist action at κ receptors (mixed agonist-antagonist). The analgesic potency of nalbuphine is equal to morphine. Nalbuphine has a short duration of action due to high lipid solubility and rapid clearance. The plasma half-life is five hours and the analgesic action lasts for three to six hours. Because of its agonist-antagonist actions, side effects like respiratory depression, urinary retention and pruritus are less likely to occur.

Dexmedetomidine, a highly selective α_2 adrenergic receptor agonist has been used as a sedative, anxiolytic, analgesic and sympatholytic [14]. Kanazi GE et al used dexmedetomidine in humans for the first time for transurethral resection of Prostate [15]. Al-Metwalli RR had shown that it enhances the postoperative analgesia after arthroscopic knee surgery [16]. Intrathecal dexmedetomidine increased the duration of analgesia when administered with local anaesthetics [17]. Analgesic action of α_2 - AR agonists is a result of the release of presynaptic C-fibre transmitters and by hyperpolarisation of postsynaptic dorsal horn neurons [18].

In this prospective randomised (simple) study, we have compared the duration of postoperative analgesia and the incidence of side effects of intrathecal nalbuphine and intrathecal dexmedetomidine in lower abdominal and lower limb surgeries.

Materials and Methods

After obtaining the approval from the hospital ethics committee, 60 patients of ASA I & II who had undergone lower abdominal and lower limb surgeries under spinal blockade were included in this prospective, randomised study (simple randomisation). Informed consent was taken from all the patients. The patients were randomly divided into two groups. Group I (n=30) patients received Inj. Bupivacaine heavy 15 mg with Inj. Nalbuphine 0.8 mg. Group II (n=30) patients received spinal anaesthesia with Inj. Bupivacaine heavy 15 mg & Inj.

Dexmedetomidine (5 mics). The following patients were excluded from the study: Patients not willing for spinal blockade, infection at the puncture site, medication with beta blockers, ARB drugs and coagulation abnormalities. Patients with spinal deformities and morbidly obese patients were also excluded. Patients were explained how to score the postoperative pain in Visual Analog Scale (VAS). They were instructed to indicate 0 to 10 depending on the severity of pain (0-no pain, 10-severe pain).

The preoperative fasting period was kept at six to eight hours. All the patients were given premedication with Inj. Ranitidine 50 mg & Inj. Ondansetron 4 mg intravenously. Standard monitors were applied in the operating room: ECG, Pulse oximetry, non-invasive blood pressure. Spinal anaesthesia was administered under strict aseptic conditions, in sitting position. L3-L4 interspace was chosen and 25G Quinck needle was used. After confirming the sub arachnoid space, patients received the above mentioned drugs according to the group. The total volume of 3.5 ml was slowly injected intrathecally. After giving the spinal blockade by using a hypodermic needle in the mid-clavicular line, the loss of sensory level was assessed and the time to achieve L1 level was recorded as onset of sensory block. The following parameters were also noted: the highest sensory level, the time taken for two segment regression time and duration of sensory block. We used modified Bromage scale to assess the motor block. Time to achieve scale 3 was considered as onset of motor block. Bromage scale: Grade 0 - no muscle weakness, Grade I - unable to flex hip, Grade II - unable to flex the knee, and Grade III - unable to flex the ankle.

The following demographic variables were noted: Age, Sex, Weight, BSA, ASA grade. Type and duration of surgery was also recorded. Hemodynamic parameters like heart rate (HR) and blood pressure (BP) were recorded at 2-minute intervals for the first 10 minutes (after the spinal blockade), and then at 15-minute intervals for the duration of the surgery. In the postoperative period, HR and BP were recorded hourly for first six hours and then at the 12th hour and 24th hour respectively.

30% fall in BP from the baseline was defined as hypotension. It was treated with fluids and Inj. Ephedrine. Bradycardia was defined as HR <50 bpm and treated with Inj. Glycopyrrolate 0.2 mg i.v. Additional analgesics were avoided in the intraoperative period. The incidence and time of bradycardia and hypotension in both groups were noted. In addition, the following adverse effects were

recorded: shivering, nausea, vomiting, decrease in O₂ saturation, and pruritus.

In the postoperative period, the time to require the first analgesic drug was noted. This interval was considered as the duration of analgesia. Mean duration of onset of sensory block and motor blockade was noted. All the above mentioned hemodynamic variables and oxygen saturation was recorded.

Statistical Analysis

The data was analysed using Chi-square and T-test where P <0.05 was considered as statistically significant.

Results

60 patients who underwent lower abdominal and lower limb surgeries were included in this study. Table 1 shows the demographic variables among the

patients in both groups. They were comparable in both groups. The mean age of the patients in Group I was 41.6± 13 and in Group II was 44.5±10.7. The mean onset of sensory block (3.5± 0.7 Vs 4.2 ± 0.8) and motor block (1.7±0.7 Vs 2.6 ± 0.9) were shown in Table 2. Both were shorter in nalbuphine group than dexmedetomidine group which was statistically significant (p = 0.002, 0.0006). The mean duration of analgesia was longer in patients who received dexmedetomidine than the nalbuphine group (197 ± 6 min Vs 99.6±6 min), which was statistically significant. The distribution of sensory level in both groups was similar. Regression of sensory level by two segments was faster in nalbuphine group (107 ± 7.9 Vs 122±6.0). Incidence of hypotension and bradycardia (Fig 1, 2& 3) were higher in dexmedetomidine group (Table 3) but amenable to medical management with fluids, Inj phenylephrine and Inj Atropine/Glycopyrrolate. The hemodynamic parameters (HR, Blood pressure) were comparable in

Table 1: Baseline Characteristics

Baseline Characteristics	NAL	DEX	P value
AGE	41.6 ± 13.0	44.5 ± 10.7	NS
WT	68.6 ± 5.3	63.5 ± 8.2	NS
BSA	1.5 ± 0.7	1.3 ± 0.6	NS

Table 2: Onset of Sensory & Motor block

Block	NAL	DEX	P Value
Onset of Sensory Block	3.5 ± 0.7	4.2 ± 0.8	0.002*
Onset of Motor Block	1.7 ± 0.7	2.6 ± 0.9	0.0006*
REG to Two Level	107 ± 7.9	122 ± 6.0	NS
Duration of Analgesia	99.6 ± 6	197 ± 6	0.00001*

Table 3: Incidence of Adverse effects

Adverse Events	NAL	DEX	CHISQ. Value	P Value
Hypotension	3	6	1.176	NS
Bradycardia	2	5	1.45	NS




Fig. 1:




Fig. 2:

both groups. There was no significant difference in side effects between both groups. The perioperative hemodynamics were comparable in both groups (Graph 1, 2 & 3).

Discussion

Spinal blockade is the most common method of providing anaesthesia for lower abdominal and lower limb surgeries. The advantages of adding opioids with local anaesthetics for spinal anaesthesia include rapid onset of action and prolonged postoperative analgesia. The major drawback of intrathecal opioids are side effects like nausea, vomiting, pruritus and respiratory depression. Opioids with agonist-antagonist activity may reduce the incidence of side effects while providing effective postoperative analgesia. Numerous drugs have been used as adjuncts with local anaesthetics for spinal anaesthesia: fentanyl, buprenorphine, midazolam, ketamine, neostigmine, nalbuphine and dexmedetomidine. Intrathecal nalbuphine potentiated the onset and extent of sensory and motor block of spinal anaesthesia and significantly increased the duration of sensory block [19]. Various authors used different doses of nalbuphine with local anaesthetics. Devendra Verma et al studied the effect of intrathecal nalbuphine and concluded that 2 mg of intrathecal nalbuphine was effective in enhancing postoperative analgesia [19]. 0.8 mg of intrathecal nalbuphine was used for postoperative analgesia after caesarean section [27].

The dose of intrathecal nalbuphine varies between studies. 0.8 mg of nalbuphine was suggested as an adequate dose without any side effects by Culebras et

al [20]. Another study by Mukerjee et al had concluded that 0.4 mg of intrathecal nalbuphine prolonged analgesia without any side effects when compared with 0.2 mg and 0.8 mg. We used 0.4 mg of nalbuphine for our study. Even though we found that the onset of motor block was faster in nalbuphine group, other studies did not [22,23].

Dexmedetomidine, when used as an adjunct to intrathecal local anaesthetics, provides prolonged postoperative analgesia. Different studies have used different doses. Even though high doses produced longer duration of analgesia, it may increase the cardiovascular complication like hypotension and bradycardia. In their study Sullivan et al suggested that 2.5 mics was the ED50 for the dexmedetomidine to inhibit C fibre response of dorsal horn neurons. We have chosen 5 mics for our study. We found that nalbuphine group had faster onset of sensory block than the dexmedetomidine group. Doses of 5, 10, and 15 mics of intrathecal dexmedetomidine had been studied and shown to produce a dose-dependent duration of analgesia with minimal side effects [24, 25 and 26]. We used 5 mics of dexmedetomidine intrathecally.

In our study, the onset of sensory and motor block was faster in nalbuphine group than dexmedetomidine group, which was statistically significant. However, the two dermatomal regressions were much slower in dexmedetomidine group. The duration of analgesia was longer in dexmedetomidine group. Intrathecal Dexmedetomidine resulted in longer duration of postoperative analgesia than intrathecal nalbuphine. Gupta et al suggested that dexmedetomidine 5 mics added to the local anaesthetics for spinal anaesthesia resulted in significant prolongation of postoperative analgesia

[28]. Eid et al have shown that the duration of analgesia is proportional to its dose. We have observed that the incidence of hypotension and bradycardia was higher in dexmedetomidine group which was managed medically without any adverse outcome [29]. More number of patients in dexmedetomidine group required treatment with Inj. Ephedrine for hypotension than nalbuphine group. This had been found in other studies also [28]. Overall, patients in both groups had similar, stable hemodynamics during the perioperative period. No statistically significant changes in HR and BP. The incidence of adverse events like nausea, vomiting and pruritus were similar in both groups.

There are few limitations in our study: even though we have done simple randomisation, it was not blinded. Our number of patients was small, not enough to have the power to identify the complications.

Conclusion

We would like to conclude that intrathecal nalbuphine (0.8mg) decrease the mean duration of onset of both sensory and motor block. Intrathecal 0.5 micsdexmedetomidine prolongs the duration of analgesia and the incidence of bradycardia and hypotension are higher in dexmedetomidine group.

References

1. Andres J, Valia JC, Gill A, Bolinches R, "Predictor of patient satisfaction with regional anesthesia" *RegAnesth* 1995; 20:498-505.
2. Roussel JR, Heindel L, "Effect of intrathecal fentanyl on duration of bupivacaine spinal blockade for outpatient knee arthroscopy" *AANA J* 1999;67(4):337-43.
3. Gandhi K, Viscui E, "Multimodal pain management techniques in hip and knee arthroplasty" *Journal of NYSORA* 2009;13:1-8.
4. Kamath S, Hosagoudar P, "Comparison of efficacy of intrathecal morphine 100ug and 200ug for post-operative pain relief in patients undergoing lower abdominal and lower limb surgeries" *J AnaesthClinPharmacol* (2009) 25(1),63-5.
5. Goodarzi M, Narasimhan RR, "The effect of large-dose intrathecal opioids on the autonomic nervous system" *AnaesthAnalg*(2001) 93(2),456-9.
6. Cole PJ, Craske DA, Wheartley RG, "Efficacy and respiratory effects of low-dose spinal morphine for postoperative analgesia following knee arthroplasty" *Br J Anaesth* (2000) 85(2),233-7.
7. Alain Borgeat, GeorgoaEkatotramis, Carlo A, Schenker, "Postoperative Nausea and Vomiting in Regional

- Anesthesia: A Review" *Anesthesiology* (2003) 98, 530-47.
8. Alhashemi JA, Kaki AM, "Effect of intrathecal tramadol administration on postoperative pain after transurethral resection of prostate" *Br J Anaesth* (2003) 91(4), 536-40.
9. Vickers MD, O'Flaherty D, Szekely SM, Read M, Yoshizumi J, Tramadol, "Pain relief by an opioid without depression of respiration" *Anaesthesia* (1992) 47, 291-6.
10. Tarkkila P, Tuominen M, Lindgren L, "Comparison of respiratory effects of tramadol and pethidine" *Eur J Anaesthesiol* (1998)15, 64-8.
11. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaugh t JL, "Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic" *J Pharmacol ExpTher* (1992) 260, 275-85.
12. Scott LJ, Perry CM, "Tramadol: a review of its use in perioperative pain" *Drugs* (2000)60, 139-76.
13. Maze M, Scarfini C and Cavaliere F, "New agents for sedation in the intensive care unit" *Crit Care Clin*, (2001)7, 881-97. I PubMed.
14. Kanazi GE, Aouad MT, Jabbour-KhourySJ, Al Jassar MD, Alameddine MM, Al-Yaman R, et al, "Effect of low-dose Dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block" *ActaAnaesthesiolScand* (2006) 50, 222-7.
15. Al-Metwalli RR, Moufi HA, Ismail SA, Siddiqui AK, Al-Ghamdi AM, Shafi MA and El-Saleh AR, "Effect of Intrarticular Dexmedetomidine on postoperative analgesia after arthroscopic knee surgery" *Br J Anaesth* (2008)101, 395-9. I ArticleI Pub Med.
16. Sudheesh K, Harsoor SS, "Dexmedetomidine in anaesthesia practice: A wonder drug?" *Indian J Anaesth* (2011) 55, 323-4 [PMCID: PPMC3190503] [PubMed: 22013245].
17. Eisenach JC, De Kock M, K limscha W, "Alpha (2)-adrenergic agonists for regional anesthesia - A clinical review of clonidine (1984)" *Anesthesiology* (1996) 655-74. [PubMed:8853097].
18. DevendraVerma, Uditanaithani, Dharm Chand Jain, Ajay Singh, "Postoperative Analgesic Efficacy Of Intrathecal Tramadol Versus Nalbuphine Added To Bupivacaine In Spinal Anaesthesia for lower limb orthopaedic surgery" *Journal of Evolution of medical and Dental sciences*. 2013 Aug 19;2(33):6196-6206.
19. Culebra X, Gaggero G, Zatloukal J, Kern C, Marti RA, "Advantages of intrathecalnalbuphine, compared with intrathecal morphine, after cesarean delivery: An evaluation of postoperative analgesia and adverse effects" *AnesthAnalg* 2000;91:601-5.
20. PallaviAhluwalia, AmitAhluwalia, RohitVarshney, Sunil Thakur, ShyamBhandari, "A Prospective Randomised Double-Blind Study to Evaluate the Effects of IntrathecalNalbuphine in Patients of Lower Abdominal Surgeries under Spinal Anaesthesia" *International Journal of Scientific Study I* June 2015;3(3):19-23.
21. Shakoo S, Bhoslr P, "Intrathecalnalbuphine: An effective adjuvant for post-operative analgesia" *Innovative J Med Health Sci* 2004;4:79-82.
22. Fournier R, Gamulin Z, Macksay M, Van Gessel E, "Intrathecal morphine versus naluphine for post operative

- pain relief after total hip replacement" *Anesthesiology* 1998;89:867-73.
23. Al-Mustafa MM, Abu-Halaweh SA, Aloweidi AS, Murshidi MM, Ammari BA, Awwad ZM, AlEdwan GM, Ramasay MA, "Effect of Dexmedetomidine added to spinal bupivacaine for urological procedures" *Saudi Med J* 2009;30(3):365-70.
24. Hala E A Eid MD, Mohammed A Shafie MD, Hend Yourssef MD et al, *Ain Shams, Journal of Anesthesiology*, 2011 July;4(2).
25. Deepika Shukla, Anil Verma, Apurva Agrawal, "Comparative study of intrathecal Dexmedetomidine with intrathecal magnesium sulfate used as adjuvants to bupivacaine" *Journal of Anaesthesiology*, 2011;27(4).
26. Hala Mostafa Goma, Nashwa Nabil Mohamed, Heba Allah Hussein Zoheir, Mohamad Saeid Ali, "A comparison between post-operative analgesia after intrathecal-nalbuphine with bupivacaine and intrathecal fentanyl with bupivacaine after cesarean section" *Egyptian Journal of Anaesthesia* 2014;30:405-410.
27. Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK, "A comparative study of intrathecal Dexmedetomidine and fentanyl as adjuvants to bupivacaine" *J Anaesthesiol Clin Pharmacol* 2011;27:339-43.
28. Gupta R, Bogra J, Verma R, Kohli M, Kushwaha JK, Kumar S, "Dexmedetomidine as an intrathecal adjuvant for postoperative analgesia" *Indian J Anaesth* 2011;55:347-51.
29. Eid HEA, Shafie MA, Youssef H, "Dose related prolongation of hyperbaric bupivacaine spinal anaesthesia by dexmedetomidine" *Ain Shams J Anesthesiol* 2011;4: 83-95.
-